GenesisCare Repairing COVID Disrupted Pathways in Breast Cancer Care with First Sunnyvale Women's Center

Article

In Partnership With

In its new Sunnyvale, Texas location, GenesisCare offers comprehensive patient-centered services for patients with breast cancer.

Sunnyvale, Texas, January 20, 2022 – GenesisCare—one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom—today announced the opening of its new Sunnyvale Women's Center with patient-friendly facilities and an experienced clinical team to this new site to provide Dallas-area residents with end-to-end, multidisciplinary breast healthcare. The comprehensive patient-centered services available include mammography, diagnosis, treatment, and post-treatment follow-up. Patients will have rapid access to advanced and innovative technologies that deliver unprecedented accuracy, faster treatment sessions, and a reduced risk of side effects.

On average, one-in-eight American women (13%)1 will develop breast cancer in their lifetime. In 2022, we will see approximately 287,8502 new cases of invasive breast cancer, along with 51,400 new non-invasive (in situ) breast cancer.

The American Cancer Society ranked Texas as the second state in the nation for having the highest number of cases per capita, with an estimated 20,900 new cases of female breast cancer with 3,420 deaths in 2021.

"The Sunnyvale Women's Center allows us to meet the need for effective, targeted diagnosis and treatment with easy, local access," shares Dr. Anita Tharian, DO, GenesisCare

Medical Oncologist. "Bridging gaps in care is especially important as regular women's screening and care being disrupted by COVID across the Dallas area."

Two-time cancer survivor and GenesisCare patient Brenda George shares, "My experiences with GenesisCare have been truly phenomenal. I began receiving treatment immediately after being diagnosed, which helped me improve my chances of fighting my cancer. My oncologist, Dr. Tharian, made my recovery her top priority."

Dr. Tharian adds, "Offering access to advanced precision medicine, like DCISionRT, has proven to help patients and doctors make informed decisions about their care. Combined with other leading technologies like AlignRT, we are also able to lower the risk of heart damage in radiation treatment for breast cancer."

The women's center's world-leading diagnostic tools and treatments use various advanced technologies to streamline the process and deliver patients' best possible life outcomes.

Innovative tools include:

AlignRT®—a surface-guided radiation therapy—provides unprecedented accuracy

and efficiency using 3-D cameras, so it pauses at the slightest movement.

DCISionRT® -delivers the most advanced Ductal Carcinoma in Situ (DCIS) test

available by looking at the biology of an individual's specific cancer using a

molecular assessment to predict risk and guide treatment plans for better outcomes.

Hologic®'s 3D mammography -new 3DimensionsTMsystem provides a more

comfortable mammography experience and higher-quality 3D images for

radiologists to find invasive cancers regardless of age or breast density.

Hologic®'s DXA system—the latest in densitometry technology—measures bone density and has a complete fracture risk assessment.

###

Related Videos
Video 5 - "Second-Line Treatment Considerations and Improving Outcomes in Breast Cancer"
Video 4 - "Impressions on Safety Data from EMERALD Subgroup Analysis"
Video 3 - "EMERALD: Elacestrant for ER+/HER2- Advanced Breast Cancer"
Video 2 - "Importance of Biomarker Testing in Breast Cancer"
Video 1 - "Patient Profile: A 49-Year-Old Woman with HR+/HER2- mBC and Liver and Lung Metastases"
Video 7 - "Unmet Needs and Future Directions in HER2+ Breast Cancer"
Video 6 - "Current Approaches to Treatment Sequencing in HER2+ Breast Cancer"
Video 5 - "Exciting Developments in HER2+ Breast Cancer"
Related Content